Ubs Group Ag Alterity Therapeutics LTD Call Options Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding ATHE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About ALTERITY THERAPEUTICS LTD

ATHE Quotes by TradingView
  • Ticker ATHE
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,114,600
  • Market Cap $86.2M
  • Description
  • Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also...
More about ATHE
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email